Decontamination of mycoplasma-contaminated Orientia tsutsugamushi strains by repeating passages through cell cultures with antibiotics

BMC Microbiology

Shuji Ando¹  Masaaki Satoh¹  Tsuneo Uchiyama²  Motohiko Ogawa¹ 

[1] Department of Virology 1, National Institute of Infectious Diseases/1-23-1, Toyama, Shinjuku-ku, Tokyo, 162-8640, Japan;Institute of Health Biosciences, The University of Tokushima Graduate School/3-18-15, Kuramoto-cho, Tokushima, 770-8503, Japan

关键词: Antibiotics;    Cell culture;    Elimination;    Contamination;    Mycoplasma;    Intracellular bacteria;    Orientia tsutsugamushi;   

Others  :  1144462
DOI  :  10.1186/1471-2180-13-32

 received in 2012-08-02, accepted in 2013-01-17,  发布年份 2013

【 摘 要 】

Background

Mycoplasmas-contamination of Orientia tsutsugamushi, one of the obligated intracellular bacteria, is a very serious problem in in vitro studies using cell cultures because mycoplasmas have significant influence on the results of scientific studies. Only a recommended decontamination method is to passage the contaminated O. tsutsugamushi strains through mice to eliminate only mycoplasmas under influence of their immunity. However, this method sometimes does not work especially for low virulent strains of O. tsutsugamushi which are difficult to propagate in mice. In this study, we tried to eliminate mycoplasmas contaminants from both high virulent and low virulent strains of the contaminated O. tsutsugamushi by repeating passage through cell cultures with antibiotics in vitro.

Results

We cultured a contaminated, high virulent strain of O. tsutsugamushi using a mouse lung fibroblasts cell line, L-929 cell in the culture medium containing lincomycin at various concentrations and repeated passages about every seven days. At the passage 5 only with 10 μg/ml of lincomycin, we did not detect mycoplasmas by two PCR based methods whereas O. tsutsugamushi continued good growth. During following four passages without lincomycin, mycoplasmas did not recover. These results suggested that mycoplasmas were completely eliminated from the high virulent strain of O. tsutsugamushi. Furthermore, by the same procedures with 10 μg/ml of lincomycin, we also eliminated mycoplasmas from a contaminated, low virulent strain of O. tsutsugamushi. Our additional assay showed that 50 μg/ml of lyncomycin did not inhibit the growth of O. tsutsugamushi, although MICs of many mycoplasmas contaminants were less than 6 μg/ml as shown previously.

Conclusion

Our results showed an alternative method to eliminate mycoplasmas from the contaminated O. tsutsugamushi strains in place of in vivo passage through mice. Especially this notable method works for the decontamination not only from the high virulent strain also from the low virulent strain of O. tsutsugamushi. For further elimination, lincomycin at the limit concentration, which does not inhibit the growth of O. tsutsugamushi, can possibly eliminate most mycoplasmas from contaminated O. tsutsugamushi strains.

【 授权许可】

   
2013 Ogawa et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Uphoff CC, Drexler HG: Eradication of mycoplasma contaminations. Methods Mol Biol 2005, 290:25-34.
• [2]Uphoff CC, Drexler HG: Elimination of mycoplasmas from infected cell lines using antibiotics. Methods Mol Biol 2011, 731:105-114.
• [3]Uphoff CC, Meyer C, Drexler HG: Elimination of mycoplasma from leukemia-lymphoma cell lines using antibiotics. Leukemia 2002, 16(2):284-288.
• [4]Tamura A, Ohashi N, Urakami H, Miyamura S: Classification of Rickettsia tsutsugamushi in a new genus, Orientia gen. nov., as Orientia tsutsugamushi comb. nov. Int J Syst Bacteriol 1995, 45(3):589-591.
• [5]Hannan PC: Antibiotic susceptibility of Mycoplasma fermentans strains from various sources and the development of resistance to aminoglycosides in vitro. J Med Microbiol 1995, 42(6):421-428.
• [6]Waites KB, Duffy LB, Schmid T, Crabb D, Pate MS, Cassell GH: In vitro susceptibilities of Mycoplasma pneumoniae, Mycoplasma hominis, and Ureaplasma urealyticum to sparfloxacin and PD 127391. Antimicrob Agents Chemother 1991, 35(6):1181-1185.
• [7]Wu CC, Shryock TR, Lin TL, Faderan M, Veenhuizen MF: Antimicrobial susceptibility of Mycoplasma hyorhinis. Vet Microbiol 2000, 76(1):25-30.
• [8]Miyamura S, Ohta T, Tamura A: Comparison of in vitro susceptibilities of Rickettsia prowazekii, R. rickettsii, R. sibirica and R. tsutsugamushi to antimicrobial agents. Nihon Saikingaku Zasshi 1989, 44(5):717-721.
• [9]Rolain JM, Maurin M, Vestris G, Raoult D: In vitro susceptibilities of 27 rickettsiae to 13 antimicrobials. Antimicrob Agents Chemother 1998, 42(7):1537-1541.
• [10]Ohno R: Antibiotic-books. [http://www.antibiotic-books.jp webcite]
• [11]Manilof J, McElhaney RN, Finch LR, Baseman JB: Mycoplasmas: molecular biology and pathogenesis. Washington D.C: American Society for Mycrobiology; 1992.
• [12]Drexler HG, Uphoff CC: Mycoplasma contamination of cell cultures: Incidence, sources, effects, detection, elimination, prevention. Cytotechnology 2002, 39(2):75-90.
• [13]Nitu Y, Hasegawa S, Kubota H: In vitro development of resistance to erythromycin, other macrolide antibiotics, and lincomycin in Mycoplasma pneumoniae. Antimicrob Agents Chemother 1974, 5(5):513-519.
• [14]Kobayashi H, Nakajima H, Shimizu Y, Eguchi M, Hata E, Yamamoto K: Macrolides and lincomycin susceptibility of Mycoplasma hyorhinis and variable mutation of domain II and V in 23S ribosomal RNA. J Vet Med Sci 2005, 67(8):795-800.
• [15]Stopler T, Branski D: Resistance of Mycoplasma pneumoniae to macrolides, lincomycin and streptogramin B. J Antimicrob Chemother 1986, 18(3):359-364.
• [16]Aarestrup FM, Friis NF: Antimicrobial susceptibility testing of Mycoplasma hyosynoviae isolated from pigs during 1968 to 1971 and during 1995 and 1996. Vet Microbiol 1998, 61(1–2):33-39.
• [17]Harwick HJ, Fekety FR Jr: The antibiotic susceptibility of Mycoplasma hominis. J Clin Pathol 1969, 22(4):483-485.
• [18]Uemura R, Sueyoshi M, Nagatomo H: Antimicrobial susceptibilities of four species of Mycoplasma isolated in 2008 and 2009 from cattle in Japan. J Vet Med Sci 2010, 72(12):1661-1663.
• [19]Hirschberg L, Bolske G, Holme T: Elimination of mycoplasmas from mouse myeloma cells by intraperitoneal passage in mice and by antibiotic treatment. Hybridoma 1989, 8(2):249-257.
• [20]Earle WR: Production of malignancy in vitro.The mouse fibroblast cultures and changes seen in the living cells. J National Cancer Res Inst 1943, 4:165-212.
• [21]Harasawa R, Mizusawa H, Nozawa K, Nakagawa T, Asada K, Kato I: Detection and tentative identification of dominant mycoplasma species in cell cultures by restriction analysis of the 16S-23S rRNA intergenic spacer regions. Res Microbiol 1993, 144(6):489-493.
• [22]Stormer M, Vollmer T, Henrich B, Kleesiek K, Dreier J: Broad-range real-time PCR assay for the rapid identification of cell-line contaminants and clinically important mollicute species. Int J Med Microbiol 2009, 299(4):291-300.
• [23]Hanaoka N, Matsutani M, Kawabata H, Yamamoto S, Fujita H, Sakata A, Azuma Y, Ogawa M, Takano A, Watanabe H, et al.: Diagnostic assay for Rickettsia japonica. Emerg Infect Dis 2009, 15(12):1994-1997.
• [24]Ogawa M, Matsumoto K, Parola P, Raoult D, Brouqui P: Expression of rOmpA and rOmpB protein in Rickettsia massiliae during the Rhipicephalus turanicus life cycle. Ann N Y Acad Sci 2006, 1078:352-356.
• [25]McClain JB, Joshi B, Rice R: Chloramphenicol, gentamicin, and ciprofloxacin against murine scrub typhus. Antimicrob Agents Chemother 1988, 32(2):285-286.